• An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study.

  NCT02406326

  CompletedObservationalUpdated Apr 11, 2018
• Clinical Study Comparing Single Long BioMimeTM Morph Coronary Stent System vs. Two Overlapping Xience Family Coronary Stent Systems in the Treatment of Patients With Long de Novo Lesions.

  NCT03721614

  Unknown statusInterventionalNot ApplicableUpdated Aug 14, 2019
• Study Safety and Performance of the Biomime Stent in Patients With Single, De Novo, Non-Complex Coronary Lesions

  NCT01507519

  CompletedInterventionalNot ApplicableUpdated Apr 5, 2018
• A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)

  NCT06412250

  RecruitingObservationalUpdated Sep 18, 2025
• Biomime Stent in All-comers PCI Patients Registry

  NCT02398955

  Unknown statusObservationalUpdated Mar 26, 2015
• BioMime Vs. Xience Randomised Control Clinical Study

  NCT02112981

  Unknown statusInterventionalNot ApplicableUpdated Aug 17, 2018

ClinicalTrials.gov ID

NCT02901353

Lead Sponsor

Meril Life Sciences Pvt. Ltd.INDUSTRY

Overall Status

Unknown status

Study Type

Observational

Enrollment

400Estimated

Last Update Posted

Feb 21, 2020Actual

Start Date

Feb 2, 2017Actual

Primary Completion Date

Dec 1, 2020Estimated

Completion Date

Dec 1, 2022Estimated

Official Title

A Prospective, Single-arm, Multi-centre, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions.

Brief Summary

A prospective, single-arm, multi-centre, observational, real world registry to evaluate safety and performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions.

Detailed Description

Title:

A prospective, single-arm, multi-centre, observational, real world registry to evaluate safety and performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions.

Short Title:

Morpheus - Global Registry Sponsor: Meril Life Sciences Pvt. Ltd

Device Used:BioMime™ Morph Sirolimus Eluting Coronary Stent System

Study population:

The utilization of the BioMime™ Morph Sirolimus Eluting Coronary Stent System implantation in very long (length ≤ 56 mm) coronary lesions in native coronary arteries with reference vessel diameter of 2.25 mm to 3.50 mm.

Enrolment:Minimum 400 patients will be enrolled

Clinical Sites:Minimum 15 sites

Objectives:Purpose of this Registry is to evaluate safety and performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System in very long (length ≤ 56 mm) coronary lesions in native coronary arteries with reference vessel diameter of 2.25 mm to 3.50 mm.

Study Design:This is a prospective, single-arm, multi-centre, observational, real world registry. All patients will be followed for up to 24 months.

Primary Outcome Measures:Freedom of target lesion failure (TLF) at 6 month and up to 24 month TLF is defined as a composite of cardiac death, myocardial infarction and target lesion revascularization.

Secondary Outcome Measures:

1. MACE at 1, 6, 12 and 24 month Defined as a composite of cardiac death, myocardial infarction attributed to the target vessel or Ischemia-driven TLR .
2. Target vessel failure at 1, 6, 12 and 24 month Defined as cardiac death, myocardial infarction attributed to the target vessel, or target vessel revascularization.
3. Academic Research Consortium (ARC) defined stent thrombosis at 1, 6, 12 and 24 months.

Definite, probable and possible stent thrombosis during acute, subacute, late and very late phase.

Other Outcome Measures:

1. Procedure Success:

   It is defined as angiographic evidence of <30% final residual stenosis of the target lesion after stent placement and no occurrence of a procedure related MACE prior to hospital discharge (for subjects with more than one lesion stented, the worse case is counted)

2. Device Success:

It is defined as angiographic evidence of <30% final residual stenosis of the target lesion using only the assigned device

• Angina Pectoris

• Sirolimus Eluting Coronary Stent System

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. The patient must be at least 18 years of age.
2. Significant native coronary artery stenosis (> 50% by visual estimate) with lesion length of ≤56mm.
3. The patient or guardian agrees to the protocol requirements and the schedule of follow-up and provides informed written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site -

Exclusion Criteria:

1. Patients contraindicated to any of the following medications: aspirin, heparin, clopidogrel, cobalt-chromium, contrast agents and sirolimus.

2. An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrolment.

3. Patients who are actively participating in another drug or device investigational study.

   -

Observational Model

Other

Time Perspective

Prospective

Lead Sponsor

Meril Life Sciences Pvt. Ltd.INDUSTRY

alhaddad63@gmail.com